AngioDynamics Inc
NASDAQ:ANGO
AngioDynamics Inc
Cash Equivalents
AngioDynamics Inc
Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
AngioDynamics Inc
NASDAQ:ANGO
|
Cash Equivalents
$44.8m
|
CAGR 3-Years
23%
|
CAGR 5-Years
10%
|
CAGR 10-Years
9%
|
|
|
Becton Dickinson and Co
NYSE:BDX
|
Cash Equivalents
$711m
|
CAGR 3-Years
-28%
|
CAGR 5-Years
5%
|
CAGR 10-Years
-22%
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Cash Equivalents
$2.5B
|
CAGR 3-Years
9%
|
CAGR 5-Years
63%
|
CAGR 10-Years
16%
|
|
|
Stryker Corp
NYSE:SYK
|
Cash Equivalents
$3.7B
|
CAGR 3-Years
7%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
7%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Cash Equivalents
$7.6B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
15%
|
CAGR 10-Years
6%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Cash Equivalents
$8.8B
|
CAGR 3-Years
131%
|
CAGR 5-Years
64%
|
CAGR 10-Years
31%
|
|
AngioDynamics Inc
Glance View
AngioDynamics, Inc. is a medical device company, which engages in the development, manufacture, and sale of medical devices for vascular access, surgery, peripheral vascular disease, and oncology. The company is headquartered in Latham, New York and currently employs 800 full-time employees. The company went IPO on 2004-05-27. Its devices are used in minimally invasive, image-guided procedures. Its product offerings include Endovascular Therapies, Oncology/Surgery (OS) and Vascular Access (VA). Its Endovascular Therapies product offerings support the medical areas of Thrombus Management, Atherectomy, Peripheral Products (Core) and Venous Insufficiency. Its OS product offerings includes a range of ablation technologies, including thermal tissue ablation systems, surgical resection and the Irreversible Electroporation (IRE) technology, the NanoKnife System. Its portfolio of VA products includes peripherally inserted central catheters (PICCs), midline catheters, implantable ports, dialysis catheters and related accessories and supplies.
See Also
What is AngioDynamics Inc's Cash Equivalents?
Cash Equivalents
44.8m
USD
Based on the financial report for Feb 28, 2025, AngioDynamics Inc's Cash Equivalents amounts to 44.8m USD.
What is AngioDynamics Inc's Cash Equivalents growth rate?
Cash Equivalents CAGR 10Y
9%
Over the last year, the Cash Equivalents growth was -43%. The average annual Cash Equivalents growth rates for AngioDynamics Inc have been 23% over the past three years , 10% over the past five years , and 9% over the past ten years .
You don't have any saved screeners yet